Aaron B. Waxman
Expertise in
9
conditions

Dr. Aaron B. Waxman

Cardiology | Intensive Care Medicine
70 Francis Street, Carl J. And Ruth Shapiro Cardiovascular Center, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
9
conditions
70 Francis Street, Carl J. And Ruth Shapiro Cardiovascular Center, 
Boston, MA 

Overview

Dr. Aaron B. Waxman is the director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital (BWH). He is also an associate professor of medicine at Harvard Medical School.After receiving his medical degree from Yale University School of Medicine, Dr. Waxman completed a residency in internal medicine at Yale New Haven Hospital. He then completed two fellowships: the first at Howard Hughes Medical Institute, and the second in pulmonary and critical care at Yale New Haven Hospital. He is board certified in critical care medicine, internal medicine and pulmonary disease.Dr. Waxman’s clinical interests include pulmonary arterial hypertension (PAH), right heart failure, thromboembolic disease and pulmonary vascular disease. His research focuses on the inflammatory mechanisms of pulmonary vascular remodeling that lead to right heart failure. His research into the regulation of cell death proteins by IL-6 cytokines in mice led to the discovery of a relationship between dyspnea and mitochondrial dysfunction, and resulted in additional clinical studies examining the abnormalities of inflammatory mediators and oxygen extraction in patients with PAH. He has authored over 110 peer-reviewed publications and has received funding from the National Institutes of Health and the National Heart, Lung, and Blood Institute.

Dr. Waxman is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Pulmonary Hypertension, Hypertension, Cor Pulmonale, Pulmonary Veno-Occlusive Disease, and Thrombectomy.

Dr. Waxman is board certified in Pulmonary Disease, Internal Medicine, and Critical Care Medicine. He is actively involved in clinical research, co-authoring 159 peer reviewed articles and participating in 19 clinical trials. Dr. Waxman is currently accepting new patients.

Specialties

Cardiology
Intensive Care Medicine

Licenses

Internal Medicine in MA

Board Certifications

Pulmonary Disease
Internal Medicine
Critical Care Medicine

Fellowships

Yale New Haven Hospital, 1994 - 1997

Hospital Affiliations

Brigham And Women's Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Brigham and Women's Hospital, Heart and Vascular Center
70 Francis Street, Carl J. And Ruth Shapiro Cardiovascular Center, Boston, MA 02115
Other Locations
Brigham and Women's Hospital, Lung Center
15 Francis Street, 2nd Floor, Boston, MA 02115
Newton-Wellesley Hospital, Division of Pulmonary and Critical Care Medicine
2000 Washington Street, Newton, MA 02462

Additional Areas of Focus

Dr. Waxman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Pulmonary Hypertension

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

An Early Feasibility Study Assessing Treatment of Pulmonary Hypertension Using the Aria CV Pulmonary Hypertension System
An Early Feasibility Study Assessing Treatment of Pulmonary Hypertension Using the Aria CV Pulmonary Hypertension System
Enrollment Status: Recruiting
Publish Date: September 29, 2025
Intervention Type: Device
Study Phase: Not Applicable
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Rodatristat Ethyl
Study Phase: Phase 2
Acute Hemodynamic Comparison of Inhaled Nitric Oxide and Inhaled Epoprostenol in Pulmonary Hypertension
Acute Hemodynamic Comparison of Inhaled Nitric Oxide and Inhaled Epoprostenol in Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: August 06, 2024
Intervention Type: Drug
Study Drugs: Vasodilator Testing (Inhaled Nitric Oxide), Vasodilator Testing (Inhaled Epoprostenol)
Study Phase: Phase 4
An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Terminated
Publish Date: December 02, 2022
Intervention Type: Drug
Study Drug: Inhaled Treprostinil
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
Enrollment Status: Terminated
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
View 9 Less Clinical Trials

159 Total Publications

Resolving Diagnostic Discordance in Group 2 Pulmonary Hypertension Through Staged Physiologic Testing: Insights From PVDOMICS.
Resolving Diagnostic Discordance in Group 2 Pulmonary Hypertension Through Staged Physiologic Testing: Insights From PVDOMICS.
Journal: medRxiv : the preprint server for health sciences
Published: June 22, 2026
Similar Doctors
Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required
Before you request

Brigham And Women's Hospital, Heart And Vascular Center

70 Francis Street, Carl J. And Ruth Shapiro Cardiovascular Center, 
Boston, MA 
 (0.1 miles away)
857-858-6125
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Scott Solomon is a Cardiologist practicing medicine in Boston, Massachusetts. Dr. Solomon is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Heart Failure with Preserved Ejection Fraction (HFpEF), Heart Failure, Atherosclerosis, Heart Bypass Surgery, and Pacemaker Implantation. Dr. Solomon is board certified in Internal Medicine. Dr. Solomon is currently accepting new patients.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required
Before you request

Brigham And Women's Hospital, Heart And Vascular Center

70 Francis Street, Carl J. And Ruth Shapiro Cardiovascular Center, 
Boston, MA 
 (0.1 miles away)
617-732-7382
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Usha B. Tedrow is director of the Clinical Cardiac Electrophysiology Program at Brigham and Women’s Hospital’s (BWH) Heart Rhythm Program. A cardiovascular medicine specialist, she is also an assistant professor of medicine at Harvard Medical School (HMS).Dr. Tedrow received her medical degree from HMS. She completed an internal medicine residency and a cardiology fellowship at Massachusetts General Hospital. In addition, she completed a cardiac electrophysiology fellowship at BWH. Dr. Tedrow is board certified in internal medicine, cardiovascular disease and cardiac electrophysiology.Her clinical interests include atrial fibrillation, cardiac resynchronization and ventricular tachycardia. She is currently researching left ventricular mapping and pacing data to analyze novel ablation treatments for structural heart disease. In addition, Dr. Tedrow serves on the editorial board of Circulation: Arrhythmia and Electrophysiology, has authored over 120 peer-reviewed publications and has received research funding from the Heart Rhythm Society. Dr. Tedrow is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Ventricular Tachycardia, Arrhythmias, Paroxysmal Supraventricular Tachycardia (PSVT), Cardiac Ablation, and Pacemaker Implantation. Dr. Tedrow is board certified in Clinical Cardiac Electrophysiology. Dr. Tedrow is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required
Before you request

Brigham And Women's Hospital

75 Francis St, 
Boston,, MA 
 (0.1 miles away)
617-732-7317
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rodney Falk is a Cardiologist practicing medicine in Boston,, Massachusetts. Dr. Falk is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Primary Amyloidosis, Cardiac Amyloidosis, Transthyretin Amyloidosis, Heart Transplant, and Cardiac Ablation. Dr. Falk is currently accepting new patients.

Frequently Asked Questions about Dr. Aaron B. Waxman

How do I make an appointment with Dr. Aaron B. Waxman?

You can book an appointment with Dr. Aaron B. Waxman by calling their office at 617-525-9733. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Aaron B. Waxman a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Aaron B. Waxman is classified as an Elite expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Aaron B. Waxman specialize in?

While Dr. Aaron B. Waxman is a Cardiology, they have specific expertise in Pulmonary Hypertension, Hypertension, and Cor Pulmonale. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Cardiology.

Does Dr. Aaron B. Waxman participate in research or clinical trials?

Yes. Dr. Aaron B. Waxman has published 159 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Dr. Aaron B. Waxman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Aaron B. Waxman accept my insurance?

Dr. Aaron B. Waxman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-525-9733 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Waxman's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile